Interferon (IFN)-α has been used in the treatment of neuroendocrine (NE) tumors; however, the feasibility of IFN-α gene therapy has not been evaluated in NE tumor cells. In this study, human IFN-α2 (hIFN-α2) gene has been transferred into a NE tumor cell line BON. hIFN-α2-expressing BON cells were subcutaneously inoculated in nude mice. The results demonstrated that hIFN-α2 exerted significant antiproliferative effects on NE tumor cell lines (BON and LCC18) and other tumor cell lines (CA46 and SW480) as well as porcine aorta cell line. Furthermore, hIFN-α2 demonstrated its antineovascular activity in mice tumor and a direct antiangiogenic effect in chicken chorioallantoic membrane assay. hIFN-α2-expressing BON cells had a stable and long-term expression. Mice implanted with hIFN-α2-expressing BON cells showed a lower incidence, a delayed development and a significantly longer doubling time of the tumor compared to both wild-type (WT) and vector group. In addition, IFN-α significantly inhibited cell adhesion of WT BON cells. hIFN-α2-expressing BON tumors had a high level of hIFN-α2 protein. Finally, mice implanted with a mixture of WT and hIFN-α2-expressing BON cells (1:1) presented a delayed tumor development and had an even lower incidence of tumors than those implanted with hIFN-α2-expressing BON cells only. The doubling time of tumor was also longest in the mixture group. Our data suggest that hIFN-α2 gene therapy might be possible to be used as a new treatment for NE tumor patients. Further studies on the regulation of hIFN-α expression are needed, especially in combination with other cytokines, which could lead to a better understanding and improvements of hIFN-α gene therapy.

Keywords:
Angiogenesis, Interferon-α, Molecular neuroendocrinology, Neuroendocrine tumors, BON cells, Mice
1.
Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 2005;19:753–781.
2.
Tagliaferri P, Caraglia M, Budillon A, et al: New pharmacokinetic and pharmacodynamic tools for interferon-α treatment of human cancer. Cancer Immunol Immunother 2005;54:1–10.
3.
Pfeffer LM, Dinarello CA, Herberman RB, et al: Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998;58:2489–2499.
4.
Bauer JA, Morrison BH, Grane RW, et al: IFN-α2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res 2003;23:3–10.
5.
Streck CJ, Zhang Y, Miyamoto R, et al: Restriction of neuroblastoma angiogenesis and growth by interferon-α/β. Surgery 2004;136:183–189.
6.
Von Marschall Z, Scholz A, Cramer T, et al: Effects of interferon α on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003;95:437–448.
7.
De Bouard S, Guillamo JS, Christov C, et al: Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-α, angiostatin, or endostatin. Hum Gene Ther 2003;14:883–895.
8.
Rosewicz S, Detjen K, Scholz A, von Marschall Z: Interferon-α: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology 2004;80(suppl 1):85–93.
9.
Hatanaka K, Suzuki K, Miura Y, et al: Interferon-α and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004;6:1139–1148.
10.
Luo Y, Chen X, Han R, O’Donnell MA: Recombinant bacille Calmette-Guérin expressing human interferon-α2b demonstrates enhanced immunogenicity. Clin Exp Immunol 2001;123:264–270.
11.
Albini A, Marchisone C, Del Grosso F, et al: Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 2000;156:1381–1393.
12.
Evers BM, Ishizuka J, Townsend CM Jr, Thompson JC: The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann NY Acad Sci 1994;733:393–406.
13.
Lundqvist M, Mark J, Funa K, et al: Characterisation of a cell line (LCC-18) from a cultured human neuroendocrine-differentiated colonic carcinoma. Eur J Cancer 1991;27:1663–1668.
14.
Zhou Y, Gobl A, Wang S, et al: Expression of p68 protein kinase and its prognostic significance during IFN-α therapy in patients with carcinoid tumours. Eur J Cancer 1998;34:2046–2052.
15.
Oki N, Matsuo H, Nakago S, et al: Effects of 3,5,3′-triiodothyronine on the invasive potential and the expression of integrins and matrix metalloproteinases in cultured early placental extravillous trophoblasts. J Clin Endocrinol Metab 2004;89:5213–5221.
16.
Zhou Y, Wang S, Gobl A, Oberg K: The interferon-α regulation of interferon regulatory factor (IRF)-1 and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol 2000;11:707–714.
17.
Kilarski WW, Jura N, Gerwins P: Inactivation of Src family kinases inhibits angiogenesis in vivo: implications for a mechanism involving organization of the actin cytoskeleton. Exp Cell Res 2003;291:70–82.
18.
Liu M, Imam H, Oberg K, Zhou Y: Gene transfer of vasostatin, a calreticulin fragment, into neuroendocrine tumor cells results in enhanced malignant behavior. Neuroendocrinology 2005;82:1–10.
19.
Hsu LC, Park JM, Zhang K, et al: The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 2004;428:341–345.
20.
Donze O, Deng J, Curran J, et al: The protein kinase PKR: a molecular clock that sequentially activates survival and death programs. EMBO J 2004;23:564–571.
21.
McCarty MF, Bielenberg D, Donawho C, et al: Evidence for the causal role of endogenous interferon-α/β in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms. Clin Exp Metastasis 2002;19:609–615.
22.
Brack SS, Dinkelborg LM, Neri D: Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging 2004;31:1327–1341.
23.
Rege TA, Fears CY, Gladson CL: Endogenous inhibitors of angiogenesis in malignant gliomas: nature’s antiangiogenic therapy. Neuro-oncology 2005;7:106–121.
24.
Kubis N, Levy BI: Understanding angiogenesis: a clue for understanding vascular malformations. J Neuroradiol 2004;31:365–368.
25.
Behrens J, Frixen U, Schipper J, et al: Cell adhesion in invasion and metastasis. Semin Cell Biol 1992;3:169–178.
26.
Van Roy F, Mareel M: Tumour invasion: effects of cell adhesion and motility. Trends Cell Biol 1992;2:163–169.
27.
Heino J: Biology of tumor cell invasion: interplay of cell adhesion and matrix degradation. Int J Cancer 1996;65:717–722.
28.
Solorzano CC, Hwang R, Baker CH, et al: Administration of optimal biological dose and schedule of interferon α combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin Cancer Res 2003;9:1858–1867.
29.
Vikman S, Essand M, Cunningham JL, et al: Gene expression in midgut carcinoid tumors: potential targets for immunotherapy. Acta Oncol 2005;44:32–40.
30.
Lindner M, Schirrmacher V: Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylene-glycol versus electro-fusion protocols. Eur J Clin Invest 2002;32:207–217.
31.
Tsugawa T, Kuwashima N, Sato H, et al: Sequential delivery of interferon-α gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 2004;11:1551–1558.
32.
Liu Y, Saxena A, Zheng C, et al: Combined α tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors. J Gene Med 2004;6:857–868.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.